<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="120297">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01536808</url>
  </required_header>
  <id_info>
    <org_study_id>2008.506</org_study_id>
    <nct_id>NCT01536808</nct_id>
  </id_info>
  <brief_title>Premature Aging and Type 2 Diabetes Mellitus: an Increased Risk of Cardiomyopathy?</brief_title>
  <acronym>R2D2</acronym>
  <official_title>Premature Aging and Type 2 Diabetes Mellitus: an Increased Risk of Cardiomyopathy?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The potential clinical implications of this study are to optimise the selection of a
      population at risk for developing a diabetic cardiomyopathy among diabetic patients in order
      to develop early therapeutic strategies to prevent the left ventricular remodelling.

      Therefore, the originality of this project is to hypothesize that :

        -  Diabetes mellitus is often associated with a premature aging syndrome

        -  Cellular senescence may potentiate the mechanisms that are involved in decreasing
           myocardial contractility in DM and,

        -  DM associated to premature aging may increase the risk of developing a cardiomyopathy
           Thus, the modulation of telomerase activity and the control of telomere length,
           together with the attenuation of the formation of reactive oxygen species, might
           represent important new targets in order to develop therapeutic tools in prevention of
           diabetic cardiomyopathy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Telomere shortening</measure>
    <time_frame>36 months</time_frame>
    <description>Investigate whether biomarkers for senescence determined from blood samples, including telomere shortening and telomerase activity in diabetic patients have an impact of left ventricular remodelling as compared with age-matched controls and biological aged control subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dysfunction by speckle tracking imaging</measure>
    <time_frame>36 months</time_frame>
    <description>Study the incidence of subtle regional myocardial dysfunction by speckle tracking imaging (longitudinal and radial systolic strain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the predictive value of alteration</measure>
    <time_frame>36 months</time_frame>
    <description>Determine the predictive value of alteration : Proteinuria, glycosylated haemoglobin, diabetes mellitus duration, blood pressure, BNP dosage, MRI diagnoses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular events</measure>
    <time_frame>36 months</time_frame>
    <description>Investigate the predictive value of all those factors( telomere shortening, telomerase activity, echo abnormalities) on cardiovascular events including MI, HF, arrhythmia; ACV</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cardiac RMI</intervention_name>
    <description>Cardiac RMI</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Analysis telomere</intervention_name>
    <description>Analysis telomere</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Stress test</intervention_name>
    <description>Stress test</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>echocardiography</intervention_name>
    <description>echocardiography</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 Diabetes mellitus

          -  40 &lt; Age &lt; 55 years old

          -  oral antidiabetic or insulin treatment

          -  No symptoms

          -  Sinus rhythm

          -  no sign or history of heart disease

          -  LVEF &gt; 55%

          -  Absence of regional left ventricular motion abnormalities.

        Exclusion Criteria:

          -  absence of sinus rhythm,

          -  silent ischemia defined as positive exercise test or positive stress
             echocardiography,

          -  history of cardiomyopathy or CAD,

          -  valvular heart disease hemodynamically significant,

          -  severe renal insufficiency defined as creatinine clearance &lt; 30 mL/min,

          -  echocardiographic images unsuitable for quantification,

          -  type 1 diabetes mellitus,

          -  Important diabetes mellitus imbalance defined as glycated hemoglobin &gt; 9% or glycemia
             &gt; 3g/L uncontrolled hypertension (&gt; 180/100 mmHg).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geneviève Dérumeaux, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon - Hôpital Louis Pradel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Laboratoire d'échocardiographie</name>
      <address>
        <city>Bron</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <lastchanged_date>March 31, 2015</lastchanged_date>
  <firstreceived_date>February 16, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes mellitus</keyword>
  <keyword>accelerated aging</keyword>
  <keyword>cellular senescence</keyword>
  <keyword>diabetic cardiomyopathy</keyword>
  <keyword>strain imaging</keyword>
  <keyword>strain rate imaging,</keyword>
  <keyword>echocardiography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Aging, Premature</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
